Management of Ischemic Cardiogenic Shock

 

 

 

By: Dr. Miguel A Quintana, FACC, FESC
Director del ICV SMB – UCIC.
Maestría en Cuidados Cardiacos Agudos
European Board Intensive and Acute Cardiac Care
Past Pte. de la SPC
Presidente de la SPCIC

Important:

The intellectual property rights to the presentations and content available on this website belong to their respective owners and/or SOLACI. Their publication on SOLACI is carried out under strict authorization for scientific, medical, and educational purposes. Any reproduction, distribution, modification, or other use is expressly prohibited without the prior written consent of the rights holders and/or SOLACI.

More articles by this author

New Antithrombotic Strategies: Do They Increase Clinical Benefits?

      By: Dr. Gustavo Olmedo F., FESC - FACC Departamento de cardiologia Hospital de Clínicas Important: The intellectual property rights to the presentations and content available on this website...

Current Indications for Statins According to Age Groups and Associated Risk Factors

    Por: Dr. Jorge Enrique Solano-López F.A.C.P Important: The intellectual property rights to the presentations and content available on this website belong to their respective owners and/or...

Surgical Aortic Valve Replacement: PARTNER 5-Year Results

    By: Fabio B. Jatene Full Professor of Cardiovascular Surgery, Medical School, University of São Paulo, Brazil Important: The intellectual property rights to the presentations and content available on...

Severe Aortic Stenosis With Low Flow, Low Gradient, and Systolic Dysfunction

  By: Rubén G. Servián C. MD Departamento de Imágenes – Hospital Central Instituto de Previsión Social (I.P.S.) Important: The intellectual property rights to the presentations and content available...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...